ANL | Ticker Profile - Titan Protect

ANL

Adlai Nortye Ltd.

Healthcare · Biotechnology · NGM

$9.95

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$708M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-35.11

Based on estimated future earnings — lower means cheaper

Rev Growth

+178.1%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-414.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$22.50

+126% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About Adlai Nortye Ltd.

Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.

https://www.adlainortye.com

Country: United States Employees: 109 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.671

Good returns relative to risk taken

Kelly Fraction

0.0082

Marginal edge — very small allocation suggested

Calmar Ratio

0.191

Drawdown risk outweighs the returns — higher risk profile

Annual Return

17.1%

Historical annualised return based on price data

Max Drawdown

-89.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.29

Moves slightly more than the broader market

52W High

$17.25

42% below the year high

52W Low

$0.88

1032% above the year low

Avg Volume

370,029

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

5.3%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.11

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

0.65

Below 1 means short-term obligations exceed liquid assets — risk flag

Quick Ratio

0.22

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-330.5%

Profit from core operations before interest and tax

Free Cash Flow

$-37,687,248

Negative — the business is spending more than it generates

Revenue (TTM)

$5M

Total revenue over the last 12 months

Net Income

$-35,528,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$46.00

Target Median

$22.50

Target Low

$20.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
6 May2026	Kevin Hern	Republican	sell	1M–5M
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K
2026-04-13	Ro Khanna	Democrat	Sale	15K–50K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go